European prevalence estimates put primary Sjögren’s syndrome under scrutiny
The question of whether primary Sjögren’s syndrome qualifies as an orphan disease is more than a semantic dispute. It affects how the condition is classified, how it is studied, and how strongly health systems prioritize diagnostic access, specialist care, and treatment development. A critical appraisal of prevalence studies in Europe sits exactly at that fault line, where epidemiology meets policy and where small differences in case definition can change the perceived size of a disease population.
Primary Sjögren’s syndrome is a chronic systemic autoimmune disease marked by glandular dysfunction and a broad clinical burden that extends well beyond dryness alone. Patients can present with fatigue, pain, extraglandular organ involvement, and a prolonged diagnostic journey that often reflects the nonspecific nature of early symptoms. In that setting, prevalence is not just a background statistic. It becomes the hinge on which orphan-disease status can turn.
Why prevalence estimates are so difficult to compare
Prevalence studies in rheumatic disease rarely speak with one voice. Differences in classification criteria, recruitment methods, clinical setting, and the background population all shape the final estimate. In primary Sjögren’s syndrome, those differences are especially consequential because the disease can be captured through specialist clinics, population registries, administrative data, or mixed strategies that do not measure the same underlying reality.
A clinic-based estimate may reflect referral patterns and diagnostic intensity more than true community frequency. A registry-based estimate can miss undiagnosed patients, especially those with milder sicca symptoms or with systemic features that are never linked back to Sjögren’s syndrome. When studies use different definitions of disease, one prevalence figure may count a patient another would exclude. The result is a literature that can look consistent on the surface while resting on sharply different assumptions.
Orphan disease status depends on more than a single number
The orphan-disease label carries regulatory and practical weight in Europe. It is typically tied to rarity thresholds, research incentives, and access pathways that can influence how quickly therapies move from concept to clinic. For a systemic autoimmune disease such as primary Sjögren’s syndrome, prevalence estimates therefore do double duty: they describe burden and they can shape classification.
The difficulty is that rarity is not always a biologic property of disease. It is often a function of how a health system counts cases. A disorder may appear uncommon in one dataset because only tertiary-center patients are identified, yet look substantially more prevalent when more complete ascertainment is used. That distinction matters when the policy question is whether the disease population is small enough to justify orphan designation or whether it is large enough to fall outside that framework.
For patients, the policy consequences are not abstract. Orphan classification can influence research attention, funding priorities, and the pace at which targeted therapies are developed. In a disease with heterogeneous manifestations and delayed diagnosis, undercounting can also blunt recognition of unmet need.
Heterogeneity is the central epidemiologic problem
Primary Sjögren’s syndrome is a disease that resists easy counting. Some patients present first to ophthalmology, some to dentistry, some to rheumatology, and others remain in primary care with symptoms that are never assembled into a coherent autoimmune diagnosis. A prevalence study that relies on a single entry point will inevitably miss part of that pathway. Even studies performed in the same country can produce different results if they use different ascertainment strategies or classification rules.
This is why a critical appraisal of European prevalence studies matters. The strength of the evidence is not only in the numeric range reported across studies, but in the quality of the methods used to generate those numbers. Who was counted? How was the diagnosis established? Were patients captured from the community or only from specialist care? Was the study built to identify established disease, early disease, or both? Each of those questions changes the answer.
The clinical burden remains larger than the classification debate
Even if a prevalence threshold places primary Sjögren’s syndrome inside or outside orphan-disease criteria, the clinical burden remains substantial. Glandular dysfunction can be persistent and disabling. Systemic manifestations can accumulate over time. Diagnostic delay can leave patients moving between specialties without a unifying explanation for symptoms that are often dismissed as nonspecific.
That burden is exactly why epidemiologic precision matters. A disease cannot be managed well if it is counted poorly. Inadequate prevalence data can lead to under-resourced care pathways, incomplete recognition of disease burden, and uncertainty about the scale of the population needing long-term follow-up.
One sentence deserves emphasis: misclassification at the population level can distort access at the bedside.
What a critical appraisal should demand from future studies
Any serious evaluation of prevalence in primary Sjögren’s syndrome should demand methodological transparency. Studies need clearly defined case criteria, explicit sources of ascertainment, and enough detail for readers to judge whether the estimate reflects the community or only the clinic. Cross-country comparisons are especially vulnerable to bias when health care systems differ in referral structure, specialist density, and diagnostic behavior.
European prevalence studies also need to address the possibility that the disease is underrecognized in routine practice. If diagnosis depends on access to rheumatology expertise, the estimate may reflect service distribution as much as disease frequency. If cases are identified only after advanced workup, early or incomplete presentations may disappear from the prevalence count altogether.
The question of orphan status will therefore remain tied to the quality of the evidence base. Without harmonized methods, prevalence estimates can support almost any conclusion a policymaker wants to reach. With better standardization, the discussion becomes more clinically meaningful: not whether the disease is conveniently rare on paper, but how many patients actually need care, how many remain undiagnosed, and how health systems should respond.
The policy stakes are inseparable from diagnostic reality
Primary Sjögren’s syndrome sits in an awkward position for European health policy because it is neither a narrowly confined disorder nor a simple high-prevalence condition. Its burden is shaped by heterogeneity, delayed recognition, and the limitations of prevalence measurement itself. If orphan designation is being considered, the evidence must rest on studies that are methodologically comparable and clinically credible.
Without that, prevalence becomes a moving target rather than a stable epidemiologic fact. And when prevalence is unstable, the line between orphan and non-orphan disease becomes equally unstable, with direct consequences for research prioritization, specialty care, and patient access to timely diagnosis.